DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3+ regulatory T cells
Authors:
- 1 January 2015
- journal article
- research article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in BioScience Trends
- Vol. 9 (5) , 307-314
Abstract
Several studies have reported that dehydroepiandrosterone (DHEA) promotes osteoblast proliferation and inhibits osteoblast apoptosis and that DHEA inhibits osteoclast maturation. However, whether DHEA regulates osteoblast differentiation remains unclear. The present study first examined the effect of DHEA on bone morphology in vivo. DHEA was found to increase bone volume (BV), bone mineral density (BMD), and the number of trabeculae in bone (Th.N) and it was found to decrease trabecular spacing in bone (Th.sp) in ovariectomized (OVX) mice. Next, the effect of DHEA on osteoblast differentiation was examined in vitro and osteoblastogenesis-related marker genes, such as Runx2, Osterix, Collagen1, and Osteocalcin, were also detected. DHEA increased osteoblast production in mesenchymal stem cells (MSCs) cultured in osteoblastogenic medium, and DHEA increased the expression of Runx2 and osterix, thereby increasing the expression of osteocalcin and collagen1. Immune cells and bone interact, so changes in immune cells were detected in vivo. DHEA increased the number of Foxp3(+) regulatory T cells (Tregs) in the spleen but it did not affect CTLA-4 or IL-10. When MSCs were treated with DHEA in the presence of Tregs, alkaline phosphatase (ALP) activity increased. Osteoblasts and adipocytes are both generated by MSCs. If osteoblast differentiation increases, adipocyte differentiation will decrease, and the reverse also holds true. DHEA was found to increase the number of adipocytes in osteoblastogenic medium but it had no effect on the number of adipocytes and expression of PPARγ mRNA in adipogenic medium. This finding suggests that osteoblasts may be involved in adipocyte production. In conclusion, the current results suggest that DHEA can improve postmenopausal osteoporosis (PMO) by up-regulating osteoblast differentiation via the up-regulation of the expression of osteoblastogenesis-related genes and via an increase in Foxp3(+) Tregs.Keywords
This publication has 32 references indexed in Scilit:
- Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal womenBMC Endocrine Disorders, 2014
- Influência do exercício físico na qualidade de vida de mulheres pós‐menopáusicas com osteoporoseRevista Brasileira de Reumatologia, 2014
- Osteoimmunology: Cross-talk between Bone and Immune CellsImmunological Investigations, 2013
- Immunology and boneThe Journal of Biochemistry, 2013
- Postmenopausal Osteoporosis: The Role of Immune System CellsJournal of Immunology Research, 2013
- The balance of osteogenic and adipogenic differentiation in human mesenchymal stem cells by matrices that mimic stepwise tissue developmentBiomaterials, 2012
- Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cellsAtherosclerosis, 2011
- Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized miceOsteoporosis International, 2008
- Controlled differentiation of stem cellsAdvanced Drug Delivery Reviews, 2008
- Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptorJournal of Molecular Endocrinology, 2007